Taking confidence from CREDENCE and navigating with SONAR: new evidence for reducing renal failure in diabetes

Peter H Winocour


CREDENCE, SONAR, renal disease, diabetes, gliflozins, endothelin antagonist

Full Text:



Pervokic V, Jardine MJ, Neal B, et al, for the CREDENCE Trial Investigators. Canaglifloizin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; published online 14 April 2019. https://doi.org/10.1056/NEJMoa1811744

Heerspink HJL , Parving H-H, Andress DL, et al, on behalf of the SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double blind randomised placebo controlled trial. Lancet 2019;393:1937–47. https://doi.org/10.1016/S0140-6736(19)30772-X

DOI: https://doi.org/10.15277/bjd.2019.209


  • There are currently no refbacks.

The Journal of the Association of British Clinical Diabetologists